Abstract
Stathmin-like 2 (STMN2) protein, a neuronal protein of the stathmin family, has been implicated in the microtubule regulatory network as a crucial element of cytoskeletal regulation. Herein, we describe that STMN2 expression increases at both mRNA and protein levels during osteogenesis of human mesenchymal stem cells derived from adipose tissue (hMADS cells) and bone marrow (hBMS cells), whereas it decreases to undetectable levels during adipogenesis. STMN2 protein is localized in both Golgi and cytosolic compartments. Its expression appears modulated in osteoblasts by nerve growth factor, dexamethasone or RhoA kinase inhibitor Y-27632 which are known effectors of osteogenesis. Thus STMN2 appears a novel marker of osteogenesis and osteoblast per se, that could play a role in the regulation of the adipocyte/osteoblast balance.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adipocytes / metabolism
-
Adipogenesis
-
Adipose Tissue / metabolism
-
Amides / pharmacology
-
Biomarkers / metabolism
-
Bone Marrow Cells / cytology
-
Bone Marrow Cells / metabolism
-
Cytosol / metabolism
-
Dexamethasone / pharmacology
-
Golgi Apparatus / metabolism
-
Humans
-
Membrane Proteins / biosynthesis*
-
Membrane Proteins / genetics
-
Mesenchymal Stem Cells / cytology
-
Mesenchymal Stem Cells / metabolism*
-
Neurons / metabolism
-
Osteoblasts / drug effects
-
Osteoblasts / metabolism
-
Osteogenesis*
-
Protein Kinase Inhibitors / pharmacology
-
Pyridines / pharmacology
-
RNA, Messenger / biosynthesis
-
RNA, Messenger / genetics
-
Stathmin
-
rho-Associated Kinases / antagonists & inhibitors
Substances
-
Amides
-
Biomarkers
-
Membrane Proteins
-
Protein Kinase Inhibitors
-
Pyridines
-
RNA, Messenger
-
STMN2 protein, human
-
Stathmin
-
Y 27632
-
Dexamethasone
-
rho-Associated Kinases